MedEffect e-Notice from Health Canada | Fibristal and Risk of Serious Liver Injury

Fibristal is a selective progesterone receptor modulator (SPRM) manufactured by Allergan Pharma Co. which is prescribed for the treatment of moderate to severe non-cancerous uterine fibroids. On March 15, 2018, Health Canada released a new MedEffect Notice indicating that, effective January 2018, Allergan Pharma Co. had updated its monograph for Fibristal to include warnings of potential severe liver damage requiring liver transplant.

Read the full posting